Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of UB-421 in Combination with ART in Viremic HIV-1 Patients
NCT04041362Phase 2Withdrawn
- Sponsor
- United BioPharma
- Start
- Apr 2020
- Primary completion
- Dec 2020
- Modality
- IgG Antibodies
01
Overview
A Phase 2 trial of semzuvolimab in human immunodeficiency virus type 1 infection (HIV-1), sponsored by United BioPharma. Planned start Apr 2020; status: withdrawn.
02
Drugs
semzuvolimab
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04041362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04041362.